ADXN — Addex Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $6.93m
- $4.85m
- CH₣0.17m
Annual cashflow statement for Addex Therapeutics, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | 20-F | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -15.4 | -20.8 | -10.6 | 7.06 | -6.73 |
| Depreciation | |||||
| Non-Cash Items | 1.06 | 3.89 | 2.04 | -11.5 | 4 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.762 | 0.158 | 0.214 | -1.23 | 0.549 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -14.7 | -16.4 | -7.99 | -5.37 | -2.17 |
| Capital Expenditures | -0.032 | -0.001 | -0.007 | -0.001 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.001 | 0.004 | 0 | 4.65 | -0.681 |
| Sale of Fixed Assets | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.03 | 0.003 | -0.007 | 4.65 | -0.681 |
| Financing Cash Flow Items | -2.33 | -0.903 | 1.02 | 0.179 | -0.038 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 16.4 | 3.1 | 5.26 | 0.105 | 1.18 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.79 | -13.5 | -3.09 | -0.524 | -1.7 |